Oramed Pharmaceuticals, Inc. (ORMP)
5.17
-0.04
(-0.77%)
USD |
NASDAQ |
Aug 26, 11:13
Oramed Pharmaceuticals Net Income (Quarterly) : 78.16M for June 30, 2026
Net Income (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 78.16M |
| March 31, 2026 | 38.31M |
| December 31, 2025 | 9.201M |
| September 30, 2025 | 48.39M |
| June 30, 2025 | 13.26M |
| March 31, 2025 | -7.642M |
| December 31, 2024 | -10.20M |
| September 30, 2024 | -19.64M |
| June 30, 2024 | 9.204M |
| March 31, 2024 | 1.534M |
| December 31, 2023 | 13.30M |
| September 30, 2023 | -3.284M |
| June 30, 2023 | -1.313M |
| March 31, 2023 | -3.611M |
| December 31, 2022 | -8.736M |
| September 30, 2022 | -7.253M |
| June 30, 2022 | -11.07M |
| March 31, 2022 | -10.71M |
| August 31, 2021 | -7.186M |
| May 31, 2021 | -5.625M |
| February 28, 2021 | -4.608M |
| November 30, 2020 | -5.57M |
| August 31, 2020 | -2.996M |
| May 31, 2020 | -2.284M |
| February 29, 2020 | -3.688M |
| Date | Value |
|---|---|
| November 30, 2019 | -2.543M |
| August 31, 2019 | -2.28M |
| May 31, 2019 | -4.072M |
| February 28, 2019 | -3.701M |
| November 30, 2018 | -4.302M |
| August 31, 2018 | -2.926M |
| May 31, 2018 | -4.354M |
| February 28, 2018 | -2.916M |
| November 30, 2017 | -2.531M |
| August 31, 2017 | -2.696M |
| May 31, 2017 | -1.965M |
| February 28, 2017 | -3.183M |
| November 30, 2016 | -2.636M |
| August 31, 2016 | -4.76M |
| May 31, 2016 | -1.996M |
| February 29, 2016 | -1.818M |
| November 30, 2015 | -2.39M |
| August 31, 2015 | -2.116M |
| May 31, 2015 | -1.583M |
| February 28, 2015 | -1.637M |
| November 30, 2014 | -1.896M |
| August 31, 2014 | -1.629M |
| May 31, 2014 | -1.828M |
| February 28, 2014 | -1.115M |
| November 30, 2013 | -1.124M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Eli Lilly & Co. | 7.095B |
| Pfizer Inc. | -246.00M |
| Yarrow Bioscience, Inc. | -2.899M |
| Liquidia Corp. | 74.72M |
| NRX Pharmaceuticals, Inc. | -16.52M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | -78.16M |
| EPS Diluted (Quarterly) | 1.839 |
| Enterprise Value | 165.37M |
| Earnings Yield | 79.51% |
| Normalized Earnings Yield | 20.28 |